高级检索
当前位置: 首页 > 详情页

Changes in Disease Failure Risk of Nasopharyngeal Carcinoma over Time: Analysis of 749 Patients with Long-Term Follow-Up

文献详情

资源类型:
机构: [1]Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Dept Radiat Oncol,Canc Ctr, Guangzhou 510060, Peoples R China; [2]Sun Yat Sen Univ, Sch Publ Hlth, Dept Med Stat & Epidemiol, Guangzhou 510060, Peoples R China; [3]Sun Yat Sen Univ, Ctr Canc, Dept Radiat Oncol, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China
出处:
ISSN:

关键词: Nasopharyngeal neoplasms Prognosis Recurrence Mortality Hazard function

摘要:
Background: The changes in the risk of disease failure over time in nasopharyngeal carcinoma (NPC) remains unknown. Methods: We analyzed 749 patients treated with intensity-modulated radiotherapy in a single center. The annual hazard rates of disease failure (recurrence or death from any cause) were estimated using the life-table method. Results: In total, 41 (5.5%), 22 (2.9%) and 129 (17.2%) patients developed local, regional and distant recurrences, respectively; 149 (19.9%) patients died. Of the 600 patients who were alive at the last follow-up, 496 (82.7%) had follow-up times longer than 6 years. The 6-year failure-free survival rate was 74.8%. Older age (> 50 years) and advanced stage (III-IVB) were independent risk factors for disease failure in multivariate analysis. The hazard curve for failure risk in the whole cohort showed a sharp peak at 2 years, changed to a gradually decreasing plateau between years 3 and 5 and then declined sharply. Subgroup analyses revealed similar hazard curves in both sexes. However, the patterns of hazard curve significantly differed between high-risk (> 50 years or stage III-IVB) and low-risk (<= 50 years or stage I-II) patients. Interpretation: The failure hazard rate in NPC didn't decline in a linear manner, but displayed a sharp peak at 2 years. The patterns of hazard function significantly differed between patients with different age and stage. Further studies are warranted to confirm our results.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学
最新[2023]版:
大类 | 3 区 医学
小类 | 4 区 肿瘤学
第一作者:
第一作者机构: [1]Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Dept Radiat Oncol,Canc Ctr, Guangzhou 510060, Peoples R China;
通讯作者:
通讯机构: [1]Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Dept Radiat Oncol,Canc Ctr, Guangzhou 510060, Peoples R China; [3]Sun Yat Sen Univ, Ctr Canc, Dept Radiat Oncol, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:46425 今日访问量:0 总访问量:3323 更新日期:2024-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号